As a Texas medical doctor and Medtronic BMP Infuse bone personal injury and product liability attorney I am providing this Infuse litigation update. According to a report by Senate investigators, Medtronic Inc., the world largest medical device maker, wrote and edited medical journal articles attributed to outside physicians, which minimized the risks of the company’s Infuse BMP-2 bone graft.
The Senate Finance Committee said that Medtronic did not disclose its role in shaping 13 key studies of InFuse. Infuse bone grafts are a $800-million a year product. The medical studies, paid for by Medtronic, failed to mention serious risks of InFuse including male sterility, infection and increased back and leg pain.
Senate investigators reported that Medtronic paid the study authors $210 million in consulting fees for unrelated work over 15 years.